Literature DB >> 17403536

Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.

Jane L Liesveld1, Jeremy Bechelli, Karen Rosell, Chaohui Lu, Gary Bridger, Gordon Phillips, Camille N Abboud.   

Abstract

Acute myelogenous leukaemia (AML) blasts transmigrate in response to SDF-1alpha. AMD3100, a novel bicyclam molecule which inhibits stromal-derived factor (SDF)-1alpha/CXCR4 interactions, inhibited the transmigration of AML blasts and inhibited outgrowth of leukemia colony forming units. AMD3100 did not abrogate stroma-mediated protection from cytarabine-mediated apoptosis, except in the case of one promyelocytic leukemic sample tested, and it did not influence adhesion of blasts to endothelial monolayers. When AML blasts were pretreated with AMD3100, the positive effects of SDF-1alpha on NOD/SCID engraftment were diminished. This work confirms that AML is influenced by the SDF-1alpha/CXCR4 axis and demonstrates that disruption of this axis by the bicyclam AMD3100 can influence AML microenvironmental interactions.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17403536      PMCID： PMC2133372          DOI： 10.1016/j.leukres.2007.02.017

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  47 in total

1.  Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic progenitor cells.

Authors:  A Hidalgo; F Sanz-Rodríguez; J L Rodríguez-Fernández; B Albella; C Blaya; N Wright; C Cabañas; F Prósper; J C Gutierrez-Ramos; J Teixidó
Journal:  Exp Hematol       Date:  2001-03       Impact factor: 3.084

2.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice.

Authors:  Q Ma; D Jones; P R Borghesani; R A Segal; T Nagasawa; T Kishimoto; R T Bronson; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

3.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

Authors:  A Peled; I Petit; O Kollet; M Magid; T Ponomaryov; T Byk; A Nagler; H Ben-Hur; A Many; L Shultz; O Lider; R Alon; D Zipori; T Lapidot
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

4.  Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.

Authors:  A Janowska-Wieczorek; L A Marquez; J M Nabholtz; M L Cabuhat; J Montaño; H Chang; J Rozmus; J A Russell; D R Edwards; A R Turner
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

5.  Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

Authors:  Sigrid Hatse; Katrien Princen; Gary Bridger; Erik De Clercq; Dominique Schols
Journal:  FEBS Lett       Date:  2002-09-11       Impact factor: 4.124

Review 6.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells.

Authors:  Tsvee Lapidot; Isabelle Petit
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

7.  Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling.

Authors:  Asaf Spiegel; Orit Kollet; Amnon Peled; Loya Abel; Arnon Nagler; Bella Bielorai; Gideon Rechavi; Josef Vormoor; Tsvee Lapidot
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

8.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.

Authors:  M Konopleva; S Konoplev; W Hu; A Y Zaritskey; B V Afanasiev; M Andreeff
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

9.  Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.

Authors:  Elwin J C Rombouts; Biljana Pavic; Bob Löwenberg; Rob E Ploemacher
Journal:  Blood       Date:  2004-03-30       Impact factor: 22.113

10.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440
View more
  20 in total

1.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

2.  Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia.

Authors:  Adriana Plesa; Youcef Chelghoum; Eve Mattei; Hélène Labussière; Mohamed Elhamri; Giovanna Cannas; Stéphane Morisset; Inès Tagoug; Mauricette Michallet; Charles Dumontet; Xavier Thomas
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

3.  CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.

Authors:  Aftab Ullah; Kaikai Wang; Pengkai Wu; David Oupicky; Minjie Sun
Journal:  Int J Nanomedicine       Date:  2019-04-26

Review 4.  The bone marrow microenvironment and leukemia: biology and therapeutic targeting.

Authors:  Edward Allan R Sison; Patrick Brown
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

5.  Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in a breast cancer cell line.

Authors:  Xiao-Ping Chen; Lin-Lin Qian; Hong Jiang; Jiang-Hua Chen
Journal:  Int J Clin Oncol       Date:  2011-04-01       Impact factor: 3.402

6.  Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.

Authors:  K E Herbert; L Demosthenous; G Wiesner; E Link; D A Westerman; N Came; D S Ritchie; S Harrison; J F Seymour; H M Prince
Journal:  Bone Marrow Transplant       Date:  2014-06-02       Impact factor: 5.483

7.  Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.

Authors:  Angela Jacobi; Sebastian Thieme; Romy Lehmann; Fernando Ugarte; Harry L Malech; Sina Koch; Christian Thiede; Katrin Müller; Martin Bornhäuser; Martin Ryser; Sebastian Brenner
Journal:  Exp Hematol       Date:  2009-12-24       Impact factor: 3.084

8.  Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

Authors:  E Weisberg; A K Azab; P W Manley; A L Kung; A L Christie; R Bronson; I M Ghobrial; J D Griffin
Journal:  Leukemia       Date:  2011-12-20       Impact factor: 11.528

Review 9.  Role of CXCR4 in the progression and therapy of acute leukaemia.

Authors:  Long Su; Zheng Hu; Yong-Guang Yang
Journal:  Cell Prolif       Date:  2021-05-29       Impact factor: 6.831

Review 10.  Role of CXCR4 in the pathogenesis of acute myeloid leukemia.

Authors:  Amnon Peled; Sigal Tavor
Journal:  Theranostics       Date:  2013-01-13       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.